The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 890-900

  Garon, Edward B ^a   Finn, Richard S ^a   Hamidi, Habib ^a   Dering, Judy ^a   Pitts, Sharon ^a   Kamranpour, Naeimeh ^a   Desai, Amrita J ^a   Hosmer, Wylie ^a   Ide, Susan ^b   Avsar, Emin ^b   Jensen, Michael Rugaard ^b   Quadt, Cornelia ^b   Liu, Manway ^c   Dubinett, Steven M ^a   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LUMINESPIB;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CONTROL; CANCER INHIBITION; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MOLECULAR CHAPERONES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESORCINOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878971471     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0998     Document Type: Article

References (49)

1. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
2. Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008;3:e0001722.
3. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
4. Powers MV, Clarke PA, Workman P. Death by chaperone: HSP90, HSP70 or both? Cell Cycle 2009;8:518-26.
5. Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, et al. A phase I study of 17-allylamino-17-demethox-ygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3456-61.
6. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008;14:8302-7.
7. Wagner AJ MJ, Chugh R, et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKI) or other sarcomas: clinical results from a phase I trial. J Clin Oncol 2008;26:Abs 10503.
8. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpres-sing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7.
9. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allyla-mino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
10. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008;10:R33.
11. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60.
12. Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chene P, Drysdale MJ, et al. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther 2010;9:906-19.
13. Samuel TA, Sessa C, Britten C, Milligan KS, Mita MM, Banerji U, et al. AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. J Clin Oncol 28:15s, 2010 (suppl; abstr 2528).
14. Kris MG JB, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's lung cancer mutation consortium (LCMC). J Clin Oncol 2011;29(suppl): abstr CRA7506.
15. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
16. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005;11:5878-85.
17. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
18. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
19. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004;3: 465-72.
20. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
21. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, et al. 18F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011;52:1684-9.
22. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005;65:6401-8.
23. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyro-sine kinase inhibitor. Lung Cancer 2012;75:161-6.
24. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008;68: 5827-38.
25. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858-66.
26. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8:620-7.
27. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011;19: 652-63.
28. Dogan T, Harms GS, Hekman M, Karreman C, Oberoi TK, Alnemri ES, et al. X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol 2008;10:1447-55.
29. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
30. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
31. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60.
32. Wong K KM, Goldman JW, Paschold EH, Horn L, Lufkin JM, Blackman RK, et al. An open-label phase II study of the Hsp90 inhibitor gane-tespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 29, 2011(suppl; abstr 7500).
33. Garon EB, Moran T, Barlesi F, Gandhi L, Sequist LV, Kim SW, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30, 2012 (suppl; abstr 7543).
34. Felip E, Carcereny E, Barlesi F, Gandhi L, Sequist LV, Kim SW, et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Annals of Onc 23[suppl 9].
35. Wilson CA DJ, Bernardo G, Rong HM, Ginther C, Ferdman R, Cook AM, et al. Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines. Breast Cancer Res 2005;7(Suppl 2):S 4.25.
36. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-neg-ative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-26.
37. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010; 9:1985-94.
38. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003;31:334-41.
39. Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung cancer 2012;76:26-31.
40. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin cancer res 2012;18:4973-85.
41. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygel-danamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
42. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007;67:3239-53.
43. Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, et al. Genetic determinants of pemetrexed responsiveness and nonrespon-siveness in non-small cell lung cancer cells. J Thorac Oncol 2010;5: 1143-51.
44. Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, et al. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett 2011;309:228-35.
45. Lotz GP, Lin H, Harst A, Obermann WM. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 2003;278:17228-35.
46. Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2008;68:1188-97.
47. Hansen JJ, Bross P, Westergaard M, Nielsen MN, Eiberg H, Bor-glum AD, et al. Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter. Hum Genet 2003;112:71-7.
48. Johnson ML YH, Hart E, Worden R, Rademaker F, Miller C, Patel JD, et al. A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). In: Proceedings of the 12th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting; Santa Monica, CA; 2012.
49. Johnson ML YH, Hart EM, Worden R, Rademaker F, Gupta R, Miller C, et al. A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). Am Soc Clin Oncol 2012. Abstract nr 3083.